Prescient Therapeutics Limited Statistics
Want to see AU:PTX full AI Analyst Report?
Prescient Therapeutics Limited (PTX) Stock Statistics & Valuation Metrics
Total Valuation
Prescient Therapeutics Limited has a market cap or net worth of AUD 68.63M. The enterprise value is AUD 55.34M.
- Market Cap
- AUD 68.63M
- Enterprise Value
- AUD 55.34M
Share Statistics
Prescient Therapeutics Limited has 1,143,850,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,143,850,000
- Owned by Insiders
- 1.74%
- Owned by Institutions
- ―
Financial Efficiency
Prescient Therapeutics Limited’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -49.23%.
- Return on Equity (ROE)
- -0.49
- Return on Assets (ROA)
- -0.43
- Return on Invested Capital (ROIC)
- -49.23%
- Return on Capital Employed (ROCE)
- -0.74
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.33M
- Employee Count
- 3
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Prescient Therapeutics Limited is -9.13. Prescient Therapeutics Limited’s PEG ratio is -0.53.
- PE Ratio
- -9.13
- PS Ratio
- 0.00
- PB Ratio
- 4.66
- Price to FCF
- -9.98
- Price to Operating Cash Flow
- -9.17
- PEG Ratio
- -0.53
Income Statement
In the last 12 months, Prescient Therapeutics Limited had revenue of 0 and earned -7.00M in profits. Earnings per share was -0.01.
- Revenue
- 0
- Gross Profit
- -110.34K
- Operating Income
- -10.59M
- Pretax Income
- -10.44M
- Net Income
- -7.00M
- EBITDA
- -10.48M
- Earnings Per Share (EPS)
- -0.01
Cash Flow
In the last 12 months, operating cash flow was -7.22M and capital expenditures -2, giving a free cash flow of -7.22M billion.
- Operating Cash Flow
- -7.22M
- Free Cash Flow
- -7.22M
- Free Cash Flow per Share
- -0.01
Dividends & Yields
Prescient Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -10.19%
- Earnings Yield
- -10.74%
Stock Price Statistics
- Beta
- 1.39
- 52-Week Price Change
- 29.17%
- 50-Day Moving Average
- 0.06
- 200-Day Moving Average
- 0.07
- Relative Strength Index (RSI)
- 54.49
- Average Volume (3m)
- 861.71K
Important Dates
Prescient Therapeutics Limited upcoming earnings date is Feb 19, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 20, 2026
- Next Earnings Date
- Feb 19, 2027
- Ex-Dividend Date
- ―
Financial Position
Prescient Therapeutics Limited as a current ratio of 7.14, with Debt / Equity ratio of 1.57%
- Current Ratio
- 7.14
- Quick Ratio
- 7.14
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.84
- Interest Coverage Ratio
- -989.90
Taxes
In the past 12 months, Prescient Therapeutics Limited has paid -3.44M in taxes.
- Income Tax
- -3.44M
- Effective Tax Rate
- 0.33
Enterprise Valuation
Prescient Therapeutics Limited EV to EBITDA ratio is -5.93, with an EV/FCF ratio of -8.60.
- EV to Sales
- 0.00
- EV to EBITDA
- -5.93
- EV to Free Cash Flow
- -8.60
- EV to Operating Cash Flow
- -8.60
Balance Sheet
Prescient Therapeutics Limited has AUD 9.03M in cash and marketable securities with AUD 222.97K in debt, giving a net cash position of AUD 8.81M billion.
- Cash & Marketable Securities
- AUD 9.03M
- Total Debt
- AUD 222.97K
- Net Cash
- AUD 8.81M
- Net Cash Per Share
- AUD 0.01
- Tangible Book Value Per Share
- AUD 0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Prescient Therapeutics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 25.27%
Scores
- Smart Score
- 6
- AI Score
- 44
